ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia.
about
A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.Pathways to Genome-targeted Therapies in Serous Ovarian Cancer.Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission.Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.TP53 in adult acute lymphoblastic leukemia.
P2860
ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
ASXL1, TP53 and IKZF3 mutation ...... s of chronic myeloid leukemia.
@en
ASXL1, TP53 and IKZF3 mutation ...... s of chronic myeloid leukemia.
@nl
type
label
ASXL1, TP53 and IKZF3 mutation ...... s of chronic myeloid leukemia.
@en
ASXL1, TP53 and IKZF3 mutation ...... s of chronic myeloid leukemia.
@nl
prefLabel
ASXL1, TP53 and IKZF3 mutation ...... s of chronic myeloid leukemia.
@en
ASXL1, TP53 and IKZF3 mutation ...... s of chronic myeloid leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
ASXL1, TP53 and IKZF3 mutation ...... is of chronic myeloid leukemia
@en
P2093
F Acquadro
F Mercadillo
J C Cigudosa
J G Talavera-Casañas
L Espinosa-Hevia
M C Carralero
R N Salgado
P2860
P2888
P356
10.1038/BCJ.2013.54
P577
2013-11-08T00:00:00Z